Eyecare company Bausch + Lomb (NYSE:BLCO) reported in Q4 CY2024, with sales up 9.1% year on year to $1.28 billion. On the ...

Eye Care Experts at Bausch and Lomb: For over 150 years, we have focused on innovation and quality in eye care products, from contact lenses and solutions to eye drops, ointments, eye vitamins ...

After completing $300 billion in healthcare deals over several decades, there is one deal Bausch and Lomb ( BLCO) chairman ...

Reports Q4 revenue $1.28B, consensus $1.25B. “Underpinning our recent success is a commitment to long-term, profitable growth,” said Brent ...

Bausch + Lomb saw a broad-based growth across its three core segments. Vision care, its largest, saw revenue rise 9% to $723 million, while surgical increased 13% to $231 million. Pharmaceuticals rose ...